Putting an ecstasy test Kit to the test: Harm reduction or harm induction?

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1238-1244

  Murray, Rebecca A ^a   Doering, Paul L ^a   Boothby, Lisa A ^c,d   Merves, Michele L ^b   McCusker, Rachel R ^b   Chronister, Chris W ^b   Goldberger, Bruce A ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c BCPS ^*  (United States)

^d BCPS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CODEINE; DEXTROMETHORPHAN; DIHYDROCODEINE; KETAMINE; MORPHINE; NORPROPOXYPHENE;

ANALYTIC METHOD; ARTICLE; DIAGNOSTIC ACCURACY; DRUG ABUSE; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG IDENTIFICATION; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; TABLET;

3,4-METHYLENEDIOXYAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; TABLETS;

EID: 0141754111     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1238.32704     Document Type: Article

References (45)

1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2002. Emergency department trends from the drug abuse warning network, final estimates 1994-2001, DAWN Series D-21, DHHS publication no. (SMA) 02-3635, Rockville, MD. Available from http://www.samhsa. gov/oas/DAWN/Final2k1EDtrends/text/EDtrend2001v6.pdf. Accessed December 26, 2002.
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Ecstasy, LSD, PCP, and other hallucinogens: data from the 2001 national household survey of drug abuse. Available from http://www.samhsa.gov/oas/ecstasy.htm. Accessed December 26, 2002.
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Lifetime use of Ecstasy, peyote, mescaline, and other hallucinogens (PDF format). Available from http://www.samhsa.gov/oas/nhsda/2k1nhsda/vol3/Sect1v1_PDF_W_106-110.pdf. Accessed December 26, 2002.
4. Drug Abuse Warning Network. The DAWN report. Available from http://www.samhsa.gov/oas/2k2/DAWNclubdrugs2k1.pdf. Accessed December 26, 2002.
5. U.S. Drug Enforcement Administration. Chemical diversion and synthetic drug manufacture. Available from http://www.usdoj.gov/dea/concern/drug_trafficking.html. Accessed February 4, 2003.
6. U.S. Department of Health and Human Services and SAMHSA's National Clearinghouse for Alcohol and Drug Information. Available from http://www.heatth.org/newsroom/rep/146.aspx. Accessed August 4, 2003.
7. U.S. Drug Enforcement Administration. The hallucinogen PMA: Dancing with death. Available from http://www.usdoj.gov/dea/pubs/intel/20025intellbrief.pdf. Accessed December 26, 2002.
8. Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J Anal Toxicol 2001;25:645-8.
9. Drug Enforcement Agency. Drug intelligence brief: club drugs, an update, September 2001. Available from http://www.usdoj. gov/dea/pubs/intel/01026/index.html. Accessed December 26, 2002.
10. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J. Chemical analysis of Ecstasy pills [letter]. JAMA 2000;284(17):2190.
11. DanceSafe. Promoting health and safety within the rave and nightclub community. Available from http://www.dancesafe. org/testingkits/orderform.php. Accessed December 24, 2002.
12. Ecstasy.org. Home page. Available from http://www.ecstasy.org/testing/index.html. Accessed December 24, 2002.
13. United States Department of Justice, Law Enforcement and Corrections. Standards and testing program. Law enforcement color test reagents/kits for preliminary identification of drugs of abuse. Available from http://www.ncjrs.org/pdffiles1/nij/183258.pdf. Accessed December 27, 2002.
14. Ecstasy.org. Marquis reagent color chart. Available from http://www.ecstasy.org/testing/db/colourchart.html. Accessed December 24, 2002.
15. Ecstasy.org. Guidance for testing pills using the Marquis reagent. Available from http://www.ecstasy.org/testing/db/pill_ test.html. Accessed December 24, 2002.
16. Wu AH, Onigbinde TA, Wong SS, Johnson KG. Identification of methamphetamines and over-the-counter sympathomimetic amines by full-scan GC-ion trap MS with electron impact and chemical ionization. J Anal Toxicol 1992;16:137-41.
17. Harm Reduction Project. Things I should know about the project. Available from http://www.ihrproject.org/index.html. Accessed December 26, 2002.
18. Evans PE, Clark HW, Hughes G, et al. Are drug treatment providers willing to participate in harm reduction and to what extent? National Institute for Drug Abuse Research monograph series. Problems of drug dependence 1994: Proceedings of the 56th annual scientific meeting, vol. II:117. Available from http://165.112.78.61/pdf/monographs/153.pdf. Accessed December 26, 2002.
19. European Monitoring Center for Drugs and Drug Addiction. An inventory of on-site pill testing interventions in the EU. Available from http://www.emcdda.org/multimedia/project_ reports/responses/pill_testing_report.pdf. Accessed December 27, 2002.
20. Winstock AR, Wolff K, Ramsey J. Ecstasy pill testing: harm minimization gone too far? Addiction 2001;96(8):1139-48.
21. Giroud C, Augsburger M, Rivier L, et al. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Toxicol 1998;22(5):227-8.
22. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accident Emerg Med 1999;16:194-7.
23. Ros JJ, Pelders MG, Egberts AC. Performance of Abusign drugs-of-abuse slide tests with particular emphasis on concentrations near the cutoff: comparison with FPIA-Adx and confirmation of results with GC-MS. J Anal Toxicol 1998;22:40-4.
24. Pellegrini M, Rosati F, Pacifici R, Zuccaro R, Romolo FS, Lopez A. Rapid screening method for determination of Ecstasy and amphetamines in urine samples using gas chromatography chemical ionization mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 2002;769(2):243-51.
25. 107th Congress. Hearing before the Subcommittee on Crime, Terrorism, and Homeland Security of the Committee on the Judiciary House of Representatives, October 10, 2002. Available from http://www.house.gov/judiciary/82263.pdf. Accessed August 4, 2003.
26. Kalant H. The pharmacology and toxicology of "ecstasy" and related drugs. Can Med Assoc J 2001;165(7):917-28.
27. Smith KM, Larive LL, Romanelli F. Club drugs: methytenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health-Syst Pharm 2002;59:1067-76.
28. De la Torre R, Ortuno J, Mas M, Farre M, Segura J. Fatal MDMA intoxication [letter]. Lancet 1999;353:593-4.
29. U.S. Drug Enforcement Administration. Ecstasy: rolling across Europe. Available from http://www.usdoj.gov/dea/pubs/intel/01008/index.html. Accessed December 26, 2002.
30. Jacobs W. Death and paramethoxyamphetamine: an evolving problem. MJA 2002;177:452. Available from http://www.mja.com.au/public/issues/177_08_211002/gibson_211002.pdf. Accessed December 27, 2002.
31. Prevention Branch, Drug and Alcohol Office, Government of Western Australia. Ecstasy teacher resource. Available from http://www.dao.health.wa.gov.au/pdf/factsheets/drugs/HP0950.p df. Accessed August 4, 2003.
32. Bellis MA, Hughes K, Lowey H. Healthy nightclubs and recreational substance use. From harm minimization to a healthy settings approach. Addict Behav 2002;27(6): 1025-35.
33. Hunter E. Carol loved partying, dancing, and her little boy The Glascow Herald (Australia) 1997. Available from http://www.erowid.org/chemicals/pma/references/media/1997_a ustralia_1.shtml. Accessed December 27, 2002.
34. Weir E. Raves: a review of the culture, the drugs and the prevention of harm. Can Med Assoc J 2000;162(13):1843-8.
35. DanceSafe. PMA warning. Available from http://www.dancesafe.org/documents/druginfo/pma_faq.php. Accessed December 27, 2002.
36. Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 1998;30:371-9.
37. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-27.
38. Morgan JF. Ecstasy use and neuropathology. Br J Psychiatry 1999;175:589.
39. Morgan JF. Toxic effect of MDMA on brain serotonin neurons [letter]. Lancet 1999;353(9160):1268-9.
40. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy: long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999;175:186-8.
41. Green RA, Goodwin GM. Ecstasy and neurodegeneration. BMJ 1996;312:1493-4.
42. McElhatton P. Teratogenic drugs: part 2. Adverse Drug React Bull 2002;214:819-22.
43. Anonymous. Acute reactions to drugs of abuse. Med Lett Drugs Ther 2002;44(1125):21-4.
44. Zagnoni PG, Albano C. Psychostimulants and epilepsy. Epilepsia 2002;43(suppl 2):28-31.
45. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002;17(6):309-12.